Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C Kapetanovic; Tore Saxne

Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic, Tore Saxne

Institut for Klinisk Medicin

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

1 Citationer (Scopus)

Abstract

Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.

Bidragets oversatte titel	[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	169
Udgave nummer	5
Sider (fra-til)	420-3
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 29 jan. 2007

Citationsformater

Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation. / Bendtzen, Klaus; Geborek, Pierre; Svenson, Morten et al.
I: Ugeskrift for Laeger, Bind 169, Nr. 5, 29.01.2007, s. 420-3.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{096063db80a3423aa2e4f1874d96263f,

title = "Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation",

abstract = "Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.",

author = "Klaus Bendtzen and Pierre Geborek and Morten Svenson and Lotta Larsson and Kapetanovic, {Meliha C} and Tore Saxne",

year = "2007",

month = jan,

day = "29",

language = "Dansk",

volume = "169",

pages = "420--3",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

TY - JOUR

T1 - Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

AU - Bendtzen, Klaus

AU - Geborek, Pierre

AU - Svenson, Morten

AU - Larsson, Lotta

AU - Kapetanovic, Meliha C

AU - Saxne, Tore

PY - 2007/1/29

Y1 - 2007/1/29

N2 - Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.

AB - Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 169

SP - 420

EP - 423

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 5

ER -